CD5 positivity and aberrant P53 expression predict primary refractoriness to first-line pola-R-CHP in patients with diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1887
Abstract: Background: The Pola-R-CHP regimen has emerged as an effective initial treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Nevertheless, a subset of patients demonstrates suboptimal responses. Identifying risk factors for primary refractoriness… read more here.
Keywords: treatment; cd5 positivity; pola; aberrant p53 ... See more keywords